Evidence for the involvement of NADPH oxidase in adenosine receptor-mediated control of coronary flow using A₁ and A₃ knockout mice

Mohammed S. El-Awady¹², Uthra Rajamani¹, Bunyen Teng¹, Stephen L. Tilley³ & S. Jamal Mustafa¹

¹ Department of Physiology and Pharmacology, Center for Cardiovascular and Respiratory Sciences and Clinical & Translational Science Institute, West Virginia University, Morgantown, West Virginia 26505
² Department of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt
³ Department of Medicine, University of North Carolina, Chapel Hill, North Carolina 27599

Keywords
Adenosine, coronary artery, isolated heart, knockout mice, NADPH oxidase.

Correspondence
S. Jamal Mustafa, Department of Physiology and Pharmacology, West Virginia University, Morgantown, WV 26505.
Tel: (304) 293-5830
Fax: (304) 293-7038
E-mail: sjmustafa@hsc.wvu.edu

Funding Information
This work was supported by National Institutes of Health (NIH) grants (HL 027339 and HL 094447 to S. J. Mustafa) and HL 071802 to S. L. Tilley.

Introduction
Adenosine is an autacoid that plays an important role in the control of coronary flow (CF) under different metabolic conditions (Berne 1963). The effects of adenosine are mediated by activation of four well-known cell surface receptors (A₁, A₂₅, A₂B, A₃) (Tabrizchi and Bedi 2001; Mustafa et al. 2009). The role of adenosine receptors (ARs) in control of CF has been studied in several species, with A₂₅ and A₃ ARs increasing CF (Flood and Headrick 2001; Sharifi Sanjani et al. 2011; Sharifi-Sanjani et al. 2013) while A₁ and A₃ ARs decrease CF (Talukder et al. 2002; Sato et al. 2005; Tawfik et al. 2006).

ARs-induced coronary responses are mediated through several effector pathways, such as cyclic adenosine 5’-monophosphate (cAMP) and potassium (K⁺) channels (Fredholm et al. 2000). Reactive oxygen species (ROS) may also play an important role in adenosine signaling pathways. In conditions such as ischemia–reperfusion and hypoxia, both ROS and adenosine are released suggesting a possible interaction between them (Zatta and Headrick 2005; Gebremedhin et al. 2010).

In the vasculature, NADPH oxidases (Nox) are the major source of ROS that play both physiological and pathophysiological roles in the control of vascular tone (Carlstrom et al. 2009). The family of Noxs consists of...
seven members, Nox1–Nox5, Doux1, and Doux2, among which Nox1, 2 (gp91 phox), and 4 are of relevance in the cardiovascular system (Schroder 2010). Several studies have shown that adenosine affects ROS generation through the regulation of Nox activity. Inhibition or knockout of Nox leads to prevention of adenosine responses in aorta (El-Awady et al. 2011), renal arterioles (Carlstrom et al. 2009), and in cerebral arteries (Gebremedhin et al. 2010), confirming an important link between ROS and adenosine.

Although ROS have been linked to adenosine responses in different tissues, little is known about the involvement of ROS in adenosine-induced CF responses. A2AARs, through MAPK signaling, were shown to regulate mouse cardiac ROS production by Nox (Ribe et al. 2008) and to attenuate reperfusion injury partly by inhibiting superoxide generation (Jordan et al. 1997). A2BARs were shown to inhibit superoxide production from mitochondrial complex I in rabbit cardiomyocytes (Yang et al. 2011). A1AR activation have been shown to reduce ROS and attenuates stunning in rat ventricular myocytes (Yang et al. 2001), while inhibiting hydrogen peroxide-induced stimulation of L-type calcium current in guinea pig ventricular myocytes (Thomas et al. 1998).

Recently from our laboratory, A1ARs activation was shown to induce contraction of the mouse aorta that is dependent on ROS generation, possibly through Nox2 (El-Awady et al. 2011). We hypothesized that ROS generation through Nox is involved in adenosine-induced CF responses. As both A1 and A3 ARs have been shown to have signaling through ROS (Narayan et al. 2001; El-Awady et al. 2011), therefore we examined the contribution of these inhibitory ARs (A1 and A3) on adenosine-induced ROS generation and vasodilation in this study. Additionally, the signaling mechanisms for both A1 and A3 ARs in relation to ROS are not clear. We used isolated hearts from wild-type (WT), A1KO, A3KO, and A1/A3DKO mice of the same background (back-crossed 12 generations to the C57 BL/6 background) were generously provided by Dr. S. Tilley.

**Material and Methods**

**Materials**

DHE was purchased from Invitrogen (Carlsbad, CA), gp91 ds-tat from Anaspec (Fremont, CA), and EUK134 from Cayman Chemical (Ann Arbor, MI). BAY 60-6583 was a gift from Bayer AG (Leverkusen, Germany). All other chemicals were purchased from Sigma-Aldrich (St. Louis, MO). Stock solutions of adenosine, apocynin, BAY 60-6583, CGS-21680, PD98059 and EUK134 were made in dimethyl sulfoxide (DMSO), whereas gp91 ds-tat was dissolved in distilled water.

**Animals**

All of the animal care and experimental protocols were performed according to the guidelines and approval of the Animal Care and Use Committee at West Virginia University. WT (C57BL/6) mice were purchased from The Jackson Laboratory (Bar Harbor, ME). A1KO, A3KO, and A1/A3DKO mice of the same background (back-crossed 12 generations to the C57 BL/6 background) were

**Langendorff-perfused mouse heart preparation**

Mice were anesthetized with pentobarbital sodium (50 mg/kg i.p.). Hearts were rapidly removed into heparinized (5 U/ml) ice-cold Krebs–Henseleit (KH) buffer containing (in mmol/L) 119 NaCl, 11 glucose, 22 NaHCO3, 4.7 KCl, 1.2 KH2PO4, 1.2 MgSO4, 2.5 CaCl2, 2 pyruvate and 0.5 EDTA. Hearts were retrogradely perfused through the aorta cannulated with a 20-gauge, blunt-ended needle at a constant pressure of 80 mmHg and continuously gassed with 95% O2–5% CO2 KH buffer at 37°C. The left atrium was removed, and a water-filled balloon was inserted into the left ventricle across the mitral valve and connected to a pressure transducer permitting continuous measurement of left ventricular developed pressure (LVDP). Balloon volume was modified to maintain a left ventricular diastolic pressure of 2–5 mmHg. CF was measured via a Transonic flow probe (Transonic Systems, Ithaca, NY) in the aortic perfusion line. Baseline CF, LVDP, and heart rate (HR) were monitored continuously and recorded on a Power Lab data-acquisition system (AD Instruments, Colorado Springs, CO). Hearts were allowed to equilibrate for 30 min before starting experimental protocols.

**Experimental protocol**

After baseline data were acquired, concentration-response curve (CRC) was performed by exposing each heart to progressively increasing concentrations of adenosine (10⁻⁸–10⁻⁵ mol/L). Each concentration of adenosine was infused for 5 min, followed by a minimum of 5 min of perfusion for drug washout. In separate experiments, the Nox inhibitor apocynin (10⁻⁵ mol/L), the specific Nox-2 inhibitor gp91 ds-tat (10⁻⁶ mol/L) or the superoxide dismutase (SOD), and catalase-mimicking drug
EUK134 (50 μmol/L) were perfused for 20 min before and during adenosine CRC. All compounds were infused at a rate of 1/100 of the CF through an injection port directly proximal to the aortic cannula using a Genie Plus Syringe pump (Kent Scientific, Torrington, CT).

**Immunoblotting**

After each experiment, hearts were rapidly collected, snap frozen in liquid nitrogen and kept at −80°C. Hearts were homogenized with 10 volumes of ice-cold RIPA buffer (Cell Signaling, Danvers, MA) with 1% Halt Protease inhibitor cocktail (Thermo Scientific, Rockford, IL) and 1 mmol/L sodium fluoride. Homogenized samples were centrifuged for 30 min at 12,000 g at 4°C. The protein content of the supernatant was determined using Bradford protein assay (BioRad, Hercules, CA).

Aliquots of the heart lysates (30 μg protein/well) were separated on NuPAGE 4–12% bis-Tris Gels (Invitrogen, Grand Island, NY). Prestained Novex Sharp Protein Standards (3.5–260 kDa, Invitrogen) were run in parallel. Proteins were transferred to nitrocellulose membranes then incubated with 5% milk for 1 h to block nonspecific binding sites. Membranes were then probed with either anti-gp91 phox (anti-Nox2) mouse monoclonal IgG (BD Biosciences, San Jose, CA), anti-Nox4 rabbit polyclonal IgG (Abcam, Cambridge, MA), anti-p47-phox rabbit polyclonal IgG (Santa Cruz Biotechnology, Santa Cruz, CA), anti-phospho extracellular signal-regulated kinase 1/2 (ERK 1/2) mouse monoclonal IgG (Santa Cruz Biotechnology) or anti-ERK 1/2 rabbit polyclonal IgG (Santa Cruz Biotechnology) at a dilution of 1:1000; anti-Nox1 rabbit polyclonal IgG (Abcam) at a dilution of 1:500, followed by incubation with secondary antibodies (horseradish peroxidase-conjugated goat anti-mouse or goat anti-rabbit; Santa Cruz Biotechnology) at 1:10,000 dilution for 1 h. After extensive washing, membranes were then stripped and reprobed with monoclonal anti-β-actin antibody (Santa Cruz Biotechnology) at a dilution of 1:20,000. For detection of bands, the membranes were treated with enhanced chemiluminescence plus (for Nox2, Nox4, p47-phox, phospho ERK 1/2, ERK 1/2, and β-actin) or advance (for Nox1) kits (GE Healthcare, Buckinghamshire, U.K.) for 1 min and subsequently exposed to ECL Hyperfilm. Relative band intensities were quantified by densitometric analysis (ImageJ 1.43u, NIH), and each sample was normalized as a ratio to either the β-actin, total p47-phox or total ERK 1/2 values as appropriate.

**Isolation of phosphoproteins**

Phosphoproteins were isolated from some hearts after the experiments using phosphoprotein purification kit (Qiagen, Hilden, Germany). Total and phospho proteins were separated on the same gel, transferred, and probed with anti-p47-phox rabbit polyclonal IgG (Santa Cruz Biotechnology) as previously mentioned in immunoblotting.

**Measurement of superoxide generation in mouse coronary artery**

Mouse coronary arteries were isolated from WT immediately prior to the experiment. The left and the right coronary branches were employed as no differences were found between left and right branches. The coronary arteries were put in culture media (Dulbecco’s modified Eagle’s medium + 10% fetal bovine serum) (ATCC, Manassas, VA) then treated with 25 μmol/L dihydroethidium (DHE) and incubated for 40 min. The arteries were then pinned and secured on a petri dish and then washed for 10 min with phosphate buffer solution. Thereafter, the arteries were maintained and treated in the same culture media until the end of the experiment. The arteries were viewed using Zeiss Violet Confocal microscope (LSM510; Heidelberg, Germany) at 40× magnification using a dipping lens (Ex/Em 480/590). An initial image of the arteries was taken under the control condition. Each artery served as its own control and treatment-related changes in ROS were compared to its own control. Once the control image was acquired, the arteries were subject to various treatments. They were treated with adenosine (10−5 mol/L), CGS-21680 (10−6 mol/L, A2A selective agonist) or BAY 60-6583 (10−6 mol/L, A2B selective agonist) for 10 min and images obtained. In separate sets of experiments, the arteries were also treated with Nox inhibitor gp91 ds-tat (10−6 mol/L) or ERK 1/2 inhibitor (PD98059, 10−5 mol/L) for 20 min and images obtained before the addition of adenosine, CGS-21680 or BAY 60-6583. Hydrogen peroxide (200 μmol/L) served as the positive control (~40% increase in intensity). To correct for the effects of quenching, a timeline control was done for 40 min to note the percentage changes in fluorescence every 5 min during the course of the experiment. On each segment of the artery, smooth muscle cells (found across the artery) and endothelial cells (found along the artery) were individually chosen and fluorescence intensity was obtained. On each treatment condition per artery the same cells were assessed for differences in ROS levels. An “n” of at least four animals was employed. Mean fluorescence intensity was calculated using ImageJ software.

**Statistical analysis**

Data were expressed as mean ± standard error of mean (SEM), where (n) equals the number of animals. The highest CF response obtained in the Langendorff experi-
ments was considered as the maximum response (Emax). Statistical analysis was carried out using Graphpad Prism software (Graphpad Software Inc., San Diego, CA). Significant differences between groups were determined with unpaired Student’s t-test or one-way analyses of variance (ANOVA) with Tukey-Kramer’s Multiple Comparisons post hoc test as appropriate. Significance level was considered when \( P < 0.05 \).

## Results

### Baseline functions of isolated hearts of WT, A1KO, A3KO, and A1/A3DKO mice

Significant baseline CF differences \((P < 0.05, n = 6)\) were observed in WT, A1KO, and A1A3DKO. A1KO and A1A3DKO had a significantly increased baseline coronary flow compared to WT animals. No significant differences were found in HR, LVDP, animal weights or heart weights between any of the KO and the WT hearts (Table 1).

### Effect of different Nox inhibitors on adenosine-mediated CF responses in WT mice isolated hearts

Adenosine caused a concentration-dependent increase in CF in WT mice (Fig. 1), with a maximum increase in CF by 270% from the baseline (100%). Inhibition of Nox by apocynin \((10^{-5} \text{ mol/L})\) or gp91 ds-tat \((10^{-6} \text{ mol/L})\) significantly \((P < 0.05, n = 6)\) decreased the enhanced CF to adenosine, where the Emax dropped from 270% to 220% (Fig. 1). This suggests that Nox activation is involved in adenosine-mediated CF responses. In addition, the SOD and catalase-mimicking agent EUK134 had effects similar to Nox inhibitors on adenosine-induced increase in CF in WT hearts (Fig. 1). EUK134 decreased the Emax for adenosine CRC to 213% from the baseline, confirming that ROS, probably produced from Nox, are involved in adenosine-induced increase in CF in WT hearts. All of these inhibitors had no effect on adenosine-induced changes in either the HR or the LVDP.

### Effect of the Nox inhibitors on adenosine-mediated CF responses in A1KO, A3KO, and A1/A3DKO mice isolated hearts

Similar to WT isolated hearts, adenosine caused a concentration-dependent increase in CF (Fig. 2), with the maximum increase of 221, 241, and 233% from the baseline in A1KO, A3KO, and A1/A3DKO isolated hearts.

### Table 1. Baseline data for WT, A1KO, A3KO, and A1/A3DKO mice isolated hearts (Langendorff).

|                  | WT               | A1KO             | A3KO             | A1/A3DKO         |
|------------------|------------------|------------------|------------------|------------------|
| Age, weeks       | 15.3 ± 0.14      | 15.8 ± 0.4       | 15.6 ± 0.2       | 16.2 ± 0.3       |
| No. of mice      | 30               | 18               | 18               | 18               |
| Body weight, g   | 22.9 ± 1.0       | 22.7 ± 1.3       | 21.6 ± 0.9       | 22.8 ± 1.1       |
| Heart weight, mg | 99.2 ± 1.9       | 99.8 ± 2.6       | 100.1 ± 3.6      | 98.9 ± 3.1       |
| Heart weight-to-body weight ratio, % | 0.43 ± 0.02 | 0.427 ± 0.01 | 0.437 ± 0.013 | 0.419 ± 0.01     |
| Coronary flow, mL/min/g heart weight | 13.54 ± 1.02 | 19.56 ± 1.72* | 16.53 ± 2.18     | 17.26 ± 1.26*    |
| Heart rate, beats/min | 349 ± 12   | 374 ± 7         | 363 ± 13         | 400 ± 7          |
| Left ventricular developed pressure, mmHg | 98 ± 6     | 95 ± 5          | 102 ± 6          | 105 ± 7          |

Values are mean ± SEM, \(n = 6\). All parameters were collected after 30 min of equilibration. WT (C57BL/6); A1KO (A1 AR knockout); A3KO (A3AR knockout) and A1/A3DKO (A1 and A3AR double knockout mice).

*A1KO and A1A3DKO had significantly higher baseline flow compared to WT.
respectively. Inhibition of Nox by apocynin (10⁻⁵ mol/L) or gp91 ds-tat (10⁻⁶ mol/L) significantly (P < 0.05, n = 6) decreased the adenosine-mediated increase in CF (Fig. 2). The Eₘₐₓ for adenosine was reduced by apocynin to 178, 194, and 188% and by gp91ds-tat to 178, 176, and 204% from the baseline in A₁KO, A₃KO and A₁/A₃DKO isolated hearts, respectively. This suggests that neither A₁ nor A₃AR is involved in adenosine-mediated increase in CF. Adenosine-induced changes in HR and LVDP were not affected by apocynin or gp91 ds-tat (10⁻⁶ mol/L) in A₁KO, A₃KO, and A₁/A₃DKO isolated hearts.

**Effect of adenosine on protein expression of Nox isoforms and phosphorylation of p47-phox in WT isolated hearts**

For further confirmation of the role of Nox in CF increase and ROS generation induced by adenosine, the protein expression levels of Nox1, 2, and 4 subunits were examined from isolated hearts. Nox1, 2, and 4 protein expression was not affected by adenosine (10⁻⁵ mol/L) treatment in WT isolated hearts (Fig. 3A). However, adenosine significantly (P < 0.05, n = 4) increased the phosphorylation of the Nox subunit p47-phox by 20% in WT mice (Fig. 3B). These data suggest that adenosine treatment may enhance Nox activation through increasing p47-phox phosphorylation but not through changes in protein expression of Nox isoforms.

**Effect of adenosine on phosphorylation of ERK 1/2 in WT isolated hearts**

ERK 1/2 phosphorylation was examined in isolated hearts as a possible signaling pathway for ROS. Adenosine significantly (P < 0.05, n = 4) increased the phosphorylation of the ERK 1/2 by 67% in WT mice (Fig. 4). These data
suggest that ERK 1/2 phosphorylation may be a possible signaling pathway for ROS and adenosine in isolated heart. This is further supported by the data presented below.

**Effect of the Nox and ERK 1/2 inhibitors on superoxide generation by adenosine and CGS-21680 from mouse coronary artery**

Adenosine (10^{-5} mol/L) treatment increased superoxide levels by 20% in coronary smooth muscle cells and 16% in coronary endothelial cells (P < 0.05, n = 4) versus untreated controls (Fig. 5B, G and H). The selective A_{2A} agonist CGS-21680 (10^{-6} mol/L) treatment showed a 24% increase in superoxide levels in coronary smooth muscle cells and a 20.75% increase in endothelial cells compared to untreated control (Fig. 5D, G and H). The selective A_{2B} agonist BAY 60-6583 (10^{-6} mol/L) did not show significant changes in superoxide production (Fig. 5F–H). Preincubation of the coronary artery with Nox inhibitor gp91 ds-tat (10^{-6} mol/L) and ERK 1/2 inhibitor PD98059 (10^{-5} mol/L) prevented adenosine and CGS-21680-mediated superoxide increase (Fig. 5G and H). These data further suggest that Nox is the source of superoxide production induced by adenosine in mouse coronary artery smooth muscle and endothelial cells. The interaction between adenosine and ROS/Nox possibly involves ERK 1/2 phosphorylation via the A_{2A}AR.

**Discussion**

This study shows a link between ROS generated through Nox, mainly Nox2, and its involvement in adenosine-induced increase in CF in isolated mouse hearts. Our data indicate that adenosine enhances Nox activation not by changes in protein expression of Nox isoforms but via increased phosphorylation of the p47-phox subunit. Furthermore, this study shows ERK 1/2 phosphorylation to
be a possible signaling mechanism through which adenosine mediates p47-phox phosphorylation. This signaling pathway is possibly through A2AAR-mediated CF effects induced by adenosine.

We used adenosine as the endogenous nonselective AR agonist in this study. Adenosine plays an important role in the control of CF under different metabolic conditions (Berne 1963). As expected, adenosine induced a large increase in CF in our isolated mouse heart model, which is well documented from studies by our lab (Morrison et al. 2002; Talukder et al. 2003; Sharifi Sanjani et al. 2011; Sharifi-Sanjani et al. 2013) and others (Flood and Headrick 2001; Sato et al. 2005).

Since both ROS and adenosine are released in conditions of stress such as ischemia–reperfusion and hypoxia probably to aid restoration of CF and oxygen supply to heart, we hypothesized a possible link between adenosine-mediated effects and ROS generation. We have shown previously that A3AR activation induces contraction of the mouse aorta which is dependent on ROS generation, possibly through Nox2 (El-Awady et al. 2011). Several other studies have shown that inhibition or absence of Nox leads to prevention of adenosine responses in renal arterioles (Carlstrom et al. 2009), and cerebral arteries (Gebremedhin et al. 2010), confirming an important link between ROS and adenosine.

In this work, we show that Nox inhibitors apocynin and gp91 ds-tat significantly attenuate the adenosine-mediated increase in CF in WT isolated hearts, suggesting that CF increase by adenosine involves Nox activation. The gp91 ds-tat is a specific inhibitor for Nox2 (Rey et al. 2001), suggesting that adenosine mainly activates Nox2. Moreover, the SOD and catalase-mimicking agent EUK134 was able to reduce the adenosine-mediated response in a way similar to Nox inhibitors, confirming the involvement of ROS in adenosine-induced increase in CF regulation. This effect of Nox inhibition at higher concentrations of adenosine (micromolar) can occur dur-
ing different physiological (such as exercise) and pathological (such as ischemia–perfusion) conditions (Berne 1963; Driver et al. 1995).

To rule out if either A1 or A3 AR is involved in a relationship between adenosine and Nox in the heart, we used A1 and A3 AR knockout mice. We used knockout animals as this approach eliminates questions on selective agonist specificity and effectiveness. In addition, selective agonists tend to lose their selectivity at higher doses. Furthermore, we used A1/A3 DKO mice to avoid any compensation or upregulation of either A1 or A3 ARs, as observed in our previous study on A2A and A2B ARs (Teng et al. 2008; Sharifi Sanjani et al. 2011). Our results show that inhibition of Nox by apocynin or gp91 ds-tat decreased adenosine-induced CF in all three KOs similar to WT. This suggests that neither A1 nor A3 ARs are involved, but possibly A2A and/or A2B ARs. Future studies in our lab using A2A and A2B AR knockout animals would throw more light on this hypothesis.

To further confirm the relationship between adenosine and Nox, we examined how adenosine affects the protein expression of different Nox isoforms (1, 2, and 4). Our previous work in mouse aorta showed that Nox2 protein expression can be increased with A2AR stimulation (El-Awady et al. 2011). However, the present data suggest that adenosine induces no changes in the different Nox isoforms protein expression in isolated hearts. Because p47-phox phosphorylation plays a major role in Nox activation and regulation (Dang et al. 2006; Thakur et al. 2010), we tested p47-phox phosphorylation in our model. Adenosine treatment in isolated heart was associated with increased phosphorylation of p47-phox subunit, confirming that Nox can be activated by adenosine in isolated hearts.

To further elucidate upstream mechanisms involving p47-phox and Nox activation, we considered ERK 1/2 as a possible upstream candidate. ERK 1/2 has been shown to be activated by adenosine in newborn rat cardiomyocytes (Germack and Dickenson 2004), mouse coronary artery smooth muscle cells (CASMCs) (Shen et al. 2005; Ansari et al. 2009), and aorta (Ponnoth et al. 2012). In addition, ERK has been shown to be involved in phosphorylation of p47-phox (El Benna et al. 1996). Our data suggest that adenosine can stimulate phosphorylation of ERK 1/2 in isolated hearts. Hence, ERK 1/2 may represent an important pathway through which adenosine can activate Nox.

Vascular Nox are activated within minutes of stimulation (Seshiah et al. 2002), producing different species of ROS, mainly superoxide anion. This superoxide can enhance vasoconstriction by rapidly converting nitric oxide (NO) to the much less active vasodilator peroxynitrite (Koppelenol et al. 1992). To measure the intracellular superoxide production induced by adenosine, we used the DHE fluorescence dye in mouse coronary arteries. Our results show that adenosine induces superoxide production in both mouse CASMCs and CAECs. In addition, the selective A2AAR agonist CGS-21680 induced a similar response as adenosine in mouse coronary artery whereas the selective A3AR agonist BAY 60-6583 did not increase superoxide levels. Previous work on rat cerebral arteries (Gebremedhin et al. 2010) has shown that both A2A and A2B ARs are involved in adenosine-induced ROS production and vasodilation. Our results reveal that there is a subtype selectivity of A2AARs involvement in ROS production in mouse coronary artery. This effect was attenuated by gp91 ds-tat, confirming that adenosine stimulates superoxide production in coronary artery (CASMCs and CAECs) through activation of Nox. Moreover, ERK 1/2 involvement was also confirmed in this AR/Nox/ROS pathway because its inhibition by PD98059 abolished the superoxide production by adenosine and its analogues.

As adenosine increased ROS in mouse coronary artery by 20%, therefore ROS is responsible for a part of adenosine responses. It is likely that there may be other signaling pathways that may contribute to this effect. Additionally, further in vivo studies will be required to examine CF responses to adenosine and contribution of myocyte-derived ROS to the adenosine-stimulated increase in CF.

A better understanding of the relationship between adenosine and ROS generation, possibly through Nox, may result in potential therapeutic targets in cardiovascular pathophysiological situations involving higher oxidative stress.

In conclusion, adenosine-induced increase in CF in isolated mouse heart involves ROS generation from Nox2. Adenosine enhances ERK 1/2 phosphorylation leading to phosphorylation and activation of p47-phox subunit with subsequent activation of Nox and release of superoxide. This relationship between adenosine and ROS/Nox involves neither A1 nor A3 ARs, but is mediated possibly through A2AARs in mice. This study, for the first time, employed freshly isolated mouse coronary arteries staining for superoxide measurement. Furthermore, the study decodes the link between adenosine and ROS-mediated coronary flow responses to be mediated via A2A ARs.

Acknowledgments

We gratefully acknowledge the excellent technical assistance of Sherry Xie for her help with Western blots. We also gratefully acknowledge help and advice given by Karen H. Martin in imaging of cells and fluorescence data analysis.
Conflict of Interest

None declared.

References

Ansari, H. R., B. Teng, A. Nadeem, K. P. Roush, K. H. Martin, J. Schnermann, et al. 2009. A1 adenosine receptor-mediated PKC and p42/p44 MAPK signaling in mouse coronary artery smooth muscle cells. Am. J. Physiol. Heart Circ. Physiol. 297:H1032–H1039.

Berne, R. M. 1963. Cardiac nucleotides in hypoxia: possible role in regulation of coronary blood flow. Legacy Content. Am. J. Physiol. 204:317–322.

Carlstrom, M., E. Y. Lai, Z. Ma, A. Patzak, R. D. Brown, and A. E. Persson. 2009. Role of NOX2 in the regulation of afferent arteriole responsiveness. Am. J. Physiol. Regul. Integr. Comp. Physiol. 296:R72–R79.

Dang, P. M., A. Stensballe, T. Boussetta, H. Raad, C. Dewas, Y. Kroviarski, et al. 2006. A specific p47phox-serine phosphorylated by convergent MAPKs mediates neutrophil NADPH oxidase priming at inflammatory sites. J. Clin. Invest. 116:2033–2043.

Driver, A. G., C. A. Kukoly, P. A. Spence, W. R. Jr Chitwood, and S. J. Mustafa. 1995. Pericardial fluid adenosine in ischemic and valvular heart disease. Chest 107:346–351.

El Benna, J., J. Han, J. W. Park, E. Schmid, R. J. Ulevitch, and Berne, R. M. 1963. Cardiac nucleotides in hypoxia: possible role in regulation of coronary blood flow. Legacy Content. Am. J. Physiol. 204:317–322.

Fredholm, B. B., G. Arslan, L. Halldner, B. Kull, G. Schulte, A. E. Persson. 2009. Role of NOX2 in the regulation of afferent arteriole responsiveness. Am. J. Physiol. Regul. Integr. Comp. Physiol. 296:R72–R79.

Gebremedhin, D., B. Weinberger, D. Lourim, and D. R. Harder. 2010. Adenosine can mediate its actions through generation of reactive oxygen species. Species Cereb. Blood Flow Metab. 30:1777–1790.

Germack, R., and J. M. Dickenson. 2004. Characterization of ERK1/2 signalling pathways induced by adenosine receptor subtypes in newborn rat cardiomyocytes. Br. J. Pharmacol. 141:329–339.

Jordan, J. E., Z. Q. Zhao, H. Sato, S. Tafi, and J. Vinten-Johansen. 1997. Adenosine A2 Receptor Activation Attenuates Reperfusion Injury by Inhibiting Neutrophil Accumulation, Superoxide Generation and Coronary Endothelial Adherence. J. Pharmacol. Exp. Ther. 280:301–309.

Koppenol, W. H., J. J. Moreno, W. A. Pryor, H. Ischiropoulos, and J. S. Beckman. 1992. Peroxynitrite, a cloaked oxidant formed by nitric oxide and superoxide. Chem. Res. Toxicol. 5:834–842.

Morrison, R. R., M. A. H. Talukder, C. Ledent, and S. J. Mustafa. 2002. Cardiac effects of adenosine in A2A receptor knockout hearts: uncovering A2B receptors. Am. J. Physiol. Heart Circ. Physiol. 282:H437–H444.

Morrison, R., M. B. Teng, and A. Pelleg. 2009. Adenosine receptors and the heart: role in regulation of coronary blood flow and cardiac electrophysiology. Handb. Exp. Pharmacol. 193:161–188.

Narayan, P., R. M. Mentzer, and R. D. Lasley. 2001. Adenosine A1 receptor activation reduces reactive oxygen species and attenuates stunning in ventricular myocytes. J. Mol. Cell. Cardiol. 33:121–129.

Ponnoth, D. S., M. A. Nayeem, S. S. Kunduri, S. L. Tilley, D. C. Zeldin, C. Ledent, et al. 2012. Role of (omega)-hydroxylase in adenosine-mediated aortic response through MAP kinase using A2A-receptor knockout mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 302:R400–R408.

Ribe, D., D. Sawbridge, S. Thakur, M. Hussey, C. Ledent, I. Kitchen, et al. 2008. Adenosine A2A receptor signaling regulation of cardiac NADPH oxidase activity. Free Radiac. Biol. Med. 44:1433–1442.

Sato, A., K. Terata, H. Miura, K. Toyama, F. R. Jr Loberiza, O. A. Hatoum, et al. 2005. Mechanism of vasodilation to adenosine in coronary arterioles from patients with heart disease. Am. J. Physiol. Heart Circ. Physiol. 288:H1633–H1640.

Schroder, K. 2010. Isoform specific functions of Nox protein-derived reactive oxygen species in the vasculature. Curr. Opin. Pharmacol. 10:122–126.

Seshiah, P. N., D. S. Weber, P. Rocic, L. Valppu, Y. Taniyama, and K. K. Griendling. 2002. Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. Circ. Res. 91:406–413.

Sharifi Sanjani, M., B. Teng, T. Krahn, S. L. Tilley, C. Ledent, and S. J. Mustafa. 2011. Contributions of A2A and A2B adenosine receptors in coronary flow responses in relation to KATP channel using A2B and A2A/2B double knockout mice. Am. J. Physiol. Heart Circ. Physiol. 301:H2322–H2333.

Sharifi-Sanjani, M., X. Zhou, S. Asano, S. Tilley, C. Ledent, B. Teng, et al. 2013. Interactions between A2A adenosine receptors, hydrogen peroxide, and KATP channels in
coronary reactive hyperemia. Am. J. Physiol. Heart Circ. Physiol. 304:H1294–H1301.
Shen, J., S. P. Halenda, M. Sturek, and P. A. Wilden. 2005. Cell-Signaling Evidence for Adenosine Stimulation of Coronary Smooth Muscle Proliferation via the A1 Adenosine Receptor. Circ. Res. 97:574–582.
Tabrizchi, R., and S. Bedi. 2001. Pharmacology of adenosine receptors in the vasculature. Pharmacol. Ther. 91:133–147.
Talukder, M. A. H., R. R. Morrison, M. A. Jacobson, K. A. Jacobson, C. Ledent, and S. J. Mustafa. 2002. Targeted deletion of adenosine A3 receptors augments adenosine-induced coronary flow in isolated mouse heart. Am. J. Physiol. Heart Circ. Physiol. 282:H2183–H2189.
Talukder, M. A., R. R. Morrison, C. Ledent, and S. J. Mustafa. 2003. Endogenous adenosine increases coronary flow by activation of both A2A and A2B receptors in mice. J. Cardiovasc. Pharmacol. 41:562–570.
Tawfik, H. E., B. Teng, R. R. Morrison, J. Schnermann, and S. J. Mustafa. 2006. Role of A1 adenosine receptor in the regulation of coronary flow. Am. J. Physiol. Heart Circ. Physiol. 291:H467–H472.
Teng, B., C. Ledent, and S. J. Mustafa. 2008. Up-regulation of A2B adenosine receptor in A2A adenosine receptor knockout mouse coronary artery. J. Mol. Cell. Cardiol. 44:905–914.
Thakur, S., J. Du, S. Hourani, C. Ledent, and J. M. Li. 2010. Inactivation of Adenosine A2A Receptor Attenuates Basal and Angiotensin II-induced ROS Production by Nox2 in Endothelial Cells. J. Biol. Chem. 285:40104–40113.
Thomas, G. P., S. M. Sims, M. A. Cook, and M. Karmazyn. 1998. Hydrogen Peroxide-Induced Stimulation of L-Type Calcium Current in Guinea Pig Ventricular Myocytes and Its Inhibition by Adenosine A1 Receptor Activation. J. Pharmacol. Exp. Ther. 286:1208–1214.
Yang, X., W. Xin, X. M. Yang, A. Kuno, T. C. Rich, M. V. Cohen, et al. 2011. A2B adenosine receptors inhibit superoxide production from mitochondrial complex I in rabbit cardiomyocytes via a mechanism sensitive to Pertussis toxin. Br. J. Pharmacol. 163:995–1006.
Zatta, A. J., and J. P. Headrick. 2005. Mediators of coronary reactive hyperaemia in isolated mouse heart. Br. J. Pharmacol. 144:576–587.